VACCINE INFLUENZA VIRUS A/17/SOUTH AFRICA/2013/01 (H1N1)PDM09 FOR PRODUCTION OF LIVE INTRANASAL INFLUENZA VACCINE FOR ADULTS AND CHILDREN

摘要

FIELD: biotechnology.;SUBSTANCE: submitted strain A/17/South Africa/2013/01 (H1N1)pdm09 is a reassortant obtained by crossing of wild virus A/South Africa/3626/2013 (H1N1)pdm09 with virus A/Leningrad/134/17/57 (H2N2) - donor of attenuation, harmless to humans. The strain of live influenza A/17/South Africa/2013/01 (H1N1)pdm09 is characterised by a set of symptoms: antigenic specificity of the epidemic virus A/17/South Africa/3626/2013 (H1N1)pdm09, temperature sensitivity and cold adaptation, harmless to laboratory animals, which correlates with human attenuation. The reassortant has inherited the genes coding surface virus antigens - hemagglutinin (HA) and neuraminidase (NA) from the epidemic parent virus, and six genes coding internal non-glycosylated proteins from the attenuation donor.;EFFECT: strain can be used in practical health care to prevent the incidence of influenza in adults and children.;5 tbl